Gencurix Inc. Logo

Gencurix Inc.

229000.KQ

(0.0)
Stock Price

1.934,00 KRW

-61.42% ROA

-105.11% ROE

-2.69x PER

Market Cap.

40.396.600.000,00 KRW

100.92% DER

0% Yield

-488.85% NPM

Gencurix Inc. Stock Analysis

Gencurix Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Gencurix Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Gencurix Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Gencurix Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Gencurix Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Gencurix Inc. Revenue
Year Revenue Growth
2015 577.789.630
2016 585.810.447 1.37%
2017 6.731.063 -8603.09%
2018 252.320.050 97.33%
2019 136.618.494 -84.69%
2020 1.571.991.617 91.31%
2021 3.046.945.886 48.41%
2022 2.559.487.184 -19.05%
2023 2.182.488.400 -17.27%
2023 2.600.317.668 16.07%
2024 2.251.557.956 -15.49%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Gencurix Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2015 469.469.239
2016 2.306.601.395 79.65%
2017 1.499.069.000 -53.87%
2018 1.439.410.000 -4.14%
2019 1.810.529.000 20.5%
2020 3.153.731.000 42.59%
2021 3.474.668.000 9.24%
2022 4.181.161.000 16.9%
2023 4.367.152.000 4.26%
2023 4.528.740.000 3.57%
2024 4.460.392.000 -1.53%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Gencurix Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 97.766.000 100%
2020 429.139.000 77.22%
2021 770.006.000 44.27%
2022 774.357.000 0.56%
2023 206.756.000 -274.53%
2023 879.761.000 76.5%
2024 953.212.000 7.71%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Gencurix Inc. EBITDA
Year EBITDA Growth
2015 -3.374.799.980
2016 -7.527.558.490 55.17%
2017 -5.797.786.120 -29.84%
2018 -5.125.869.710 -13.11%
2019 -5.691.515.080 9.94%
2020 -9.154.122.510 37.83%
2021 -12.310.515.090 25.64%
2022 -10.515.049.770 -17.08%
2023 -12.857.442.520 18.22%
2023 -10.985.057.310 -17.04%
2024 -10.499.360.400 -4.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Gencurix Inc. Gross Profit
Year Gross Profit Growth
2015 -305.967.861
2016 -608.059.394 49.68%
2017 -523.357.937 -16.18%
2018 -401.765.995 -30.26%
2019 -861.184.440 53.35%
2020 -1.356.160.891 36.5%
2021 -3.273.178.973 58.57%
2022 945.416.150 446.22%
2023 1.079.962.160 12.46%
2023 422.033.406 -155.89%
2024 215.411.824 -95.92%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Gencurix Inc. Net Profit
Year Net Profit Growth
2015 -3.981.919.817
2016 -9.063.948.157 56.07%
2017 -6.819.877.293 -32.9%
2018 -5.724.463.484 -19.14%
2019 -9.162.256.485 37.52%
2020 33.108.403.240 127.67%
2021 -34.670.022.631 195.5%
2022 -24.596.962.223 -40.95%
2023 -24.658.085.160 0.25%
2023 -19.260.021.046 -28.03%
2024 -16.216.414.332 -18.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Gencurix Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -905
2016 -1.879 51.84%
2017 -1.298 -44.87%
2018 -1.011 -28.42%
2019 -1.512 33.16%
2020 4.987 130.3%
2021 -4.737 205.3%
2022 -3.310 -43.08%
2023 -2.024 -63.54%
2023 -1.629 -24.25%
2024 -1.123 -45.19%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Gencurix Inc. Free Cashflow
Year Free Cashflow Growth
2015 -3.706.894.277
2016 -6.658.977.533 44.33%
2017 -5.628.616.128 -18.31%
2018 -5.655.377.979 0.47%
2019 -6.374.390.075 11.28%
2020 -14.900.891.560 57.22%
2021 -9.837.058.200 -51.48%
2022 -23.498.303.037 58.14%
2023 -2.930.881.700 -701.75%
2023 -13.053.902.409 77.55%
2024 -1.833.682.296 -611.9%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Gencurix Inc. Operating Cashflow
Year Operating Cashflow Growth
2015 -2.269.091.712
2016 -5.981.751.933 62.07%
2017 -5.408.516.102 -10.6%
2018 -5.033.560.206 -7.45%
2019 -5.222.008.254 3.61%
2020 -13.587.563.335 61.57%
2021 -8.366.162.665 -62.41%
2022 -10.452.261.269 19.96%
2023 -2.821.667.920 -270.43%
2023 -10.876.925.497 74.06%
2024 -1.802.293.092 -503.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Gencurix Inc. Capital Expenditure
Year Capital Expenditure Growth
2015 1.437.802.565
2016 677.225.600 -112.31%
2017 220.100.026 -207.69%
2018 621.817.773 64.6%
2019 1.152.381.821 46.04%
2020 1.313.328.225 12.25%
2021 1.470.895.535 10.71%
2022 13.046.041.768 88.73%
2023 109.213.780 -11845.42%
2023 2.176.976.912 94.98%
2024 31.389.204 -6835.43%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Gencurix Inc. Equity
Year Equity Growth
2015 6.602.425.830
2016 8.203.807.505 19.52%
2017 6.405.767.528 -28.07%
2018 9.124.457.812 29.8%
2019 155.180.607 -5779.9%
2020 53.910.975.241 99.71%
2021 31.042.476.851 -73.67%
2022 5.673.206.734 -447.18%
2023 17.976.959.820 68.44%
2023 12.003.304.356 -49.77%
2024 8.571.636.347 -40.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Gencurix Inc. Assets
Year Assets Growth
2015 9.190.425.633
2016 9.232.612.882 0.46%
2017 7.361.550.707 -25.42%
2018 10.383.232.318 29.1%
2019 2.387.519.397 -334.9%
2020 63.977.712.479 96.27%
2021 55.286.981.927 -15.72%
2022 37.238.665.245 -48.47%
2023 36.967.497.450 -0.73%
2023 33.501.909.441 -10.34%
2024 23.947.135.425 -39.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Gencurix Inc. Liabilities
Year Liabilities Growth
2015 2.587.999.803
2016 1.028.805.376 -151.55%
2017 955.783.179 -7.64%
2018 1.258.774.506 24.07%
2019 2.232.338.790 43.61%
2020 10.066.737.238 77.82%
2021 24.244.505.076 58.48%
2022 31.565.458.511 23.19%
2023 18.990.537.630 -66.22%
2023 21.498.605.085 11.67%
2024 15.375.499.078 -39.82%

Gencurix Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
201.77
Net Income per Share
-986.36
Price to Earning Ratio
-2.69x
Price To Sales Ratio
13.86x
POCF Ratio
-4.13
PFCF Ratio
-3.52
Price to Book Ratio
3.61
EV to Sales
17.28
EV Over EBITDA
-4.91
EV to Operating CashFlow
-5.44
EV to FreeCashFlow
-4.39
Earnings Yield
-0.37
FreeCashFlow Yield
-0.28
Market Cap
40,40 Bil.
Enterprise Value
50,37 Bil.
Graham Number
4035.38
Graham NetNet
-923.23

Income Statement Metrics

Net Income per Share
-986.36
Income Quality
0.65
ROE
-1.05
Return On Assets
-0.59
Return On Capital Employed
-1.06
Net Income per EBT
0.94
EBT Per Ebit
1.3
Ebit per Revenue
-4.01
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
1.36
Research & Developement to Revenue
1.53
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.24
Operating Profit Margin
-4.01
Pretax Profit Margin
-5.19
Net Profit Margin
-4.89

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-640.99
Free CashFlow per Share
-794.98
Capex to Operating CashFlow
-0.24
Capex to Revenue
0.76
Capex to Depreciation
1.57
Return on Invested Capital
-0.54
Return on Tangible Assets
-0.61
Days Sales Outstanding
168.47
Days Payables Outstanding
2.76
Days of Inventory on Hand
85.2
Receivables Turnover
2.17
Payables Turnover
132.2
Inventory Turnover
4.28
Capex per Share
153.99

Balance Sheet

Cash per Share
53,57
Book Value per Share
593,44
Tangible Book Value per Share
541.55
Shareholders Equity per Share
733.76
Interest Debt per Share
786.98
Debt to Equity
1.01
Debt to Assets
0.45
Net Debt to EBITDA
-0.97
Current Ratio
0.22
Tangible Asset Value
7,82 Bil.
Net Current Asset Value
-12,51 Bil.
Invested Capital
4255319251
Working Capital
-10,06 Bil.
Intangibles to Total Assets
0.03
Average Receivables
1,46 Bil.
Average Payables
0,01 Bil.
Average Inventory
566594882
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Gencurix Inc. Dividends
Year Dividends Growth

Gencurix Inc. Profile

About Gencurix Inc.

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.

CEO
Sung-Rai Cho
Employee
69
Address
Hanhwa Bizmetro
Seoul, 152-733

Gencurix Inc. Executives & BODs

Gencurix Inc. Executives & BODs
# Name Age
1 Sung-Rai Cho
Chief Executive Officer
70

Gencurix Inc. Competitors